Mid-Del Therapeutic Center, Inc. - Page 5




                                                - 5 -                                                  

            abused his discretion in making that determination under section                           
            446(b).  See RCA Corp. v. United States, 664 F.2d 881, 886 (2d                             
            Cir. 1981).  Consequently, at trial, petitioners had the burden                            
            of proving that respondent’s determination was arbitrary,                                  
            capricious, or without sound basis in fact or law.  See Knight-                            
            Ridder Newspapers, Inc. v. United States, supra.                                           
                  After these cases were tried but before the opinion was                              
            issued, the Court’s opinion was filed in Osteopathic Med.                                  
            Oncology & Hematology, P.C. v. Commissioner, 113 T.C. 376 (1999),                          
            which presented facts strikingly similar to those involved in the                          
            present cases.  In Osteopathic Med. Oncology & Hematology, P.C.,                           
            a taxpayer, specializing in the treatment of cancer through                                
            chemotherapy, used the cash method to expense the cost of drugs                            
            used during treatments.  The Commissioner argued that the drugs                            
            were merchandise under section 1.471-1, Income Tax Regs., and,                             
            therefore, the taxpayer had to use the accrual method to report                            
            income and costs attributable to the drugs.  This Court held that                          
            the drugs were not merchandise and that the taxpayer properly                              
            used the cash method to expense the cost of the drugs and report                           
            income.  Osteopathic Med. Oncology & Hematology, P.C., was not                             
            appealed, and the decision became final on April 7, 2000.  See                             
            secs. 7481(a)(1), 7483; cf. Fed. R. App. P. 13(a).                                         
                  In Mid-Del Therapeutic Ctr., Inc. v. Commissioner, T.C.                              
            Memo. 2000-130 (Mid-Del I), we held that respondent’s                                      





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next

Last modified: May 25, 2011